

05 July 2023

09:00-13:00

MINUTES - Agreed on 20 July 2023

**Location:** Web-conference

**Attendees:**

- **Panel Members:** Pauline Adriaanse, Annette Aldrich, Philippe Berny, Tamara Coja, Sabine Duquesne, Andreas Focks, Antonio Hernandez-Jerez (chair), Marina Marinovich, Maurice Millet, Olavi Pelkonen, Christopher Topping, Anneli Widenfalk, Martin Wilks, Gerrit Wolterink

- **Hearing Experts:** Not Applicable

- **European Commission and/or Member States representatives:** Karin Nienstedt

- **EFSA:**

PREV UNIT: Sofia Batista Leite, Marco Binaglia, Arianna Chiusolo, Ana Cioca, Katia Chukwubike, Federica Crivellente, Lucien Ferreira da Costa, Dimitra Kardassi, Anna Lanzoni, Renata Leuschner, Jochem Louisse, Javier Martinez, Martina Panzarea, Juan Parra Morte, Andrea Terron

PLANTS Unit: Fernando Alvarez, Maria Arena, Gabriella Fait, Aude Kienzler, Roberto Lava, Renata Leuschner, Alberto Linguadoca, Chris Lythgo, Oriol Magrans Soria, Laura Padovani, Vincenzo Padricello, Sharp Rachel, Simone Rizzuto, Agnès Rortais

MESE Unit: Laura Martino, Jose Cortiñas Abrahantes

## 1. Welcome and apologies for absence

The Chair welcomed the participants.

Apologies received from Aaldrik Tiktak and Silvia Pieper

## 2. Adoption of agenda

The agenda was adopted without changes.

## 3. Declarations of Interest of Panel members

In accordance with EFSA's Policy on Independence<sup>1</sup> and the Decision of the Executive Director on Competing Interest Management<sup>2</sup>, EFSA screened the Annual Declarations of Interest filled out by the Panel members invited to the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process. With regard to this meeting, Martin Wilks orally declared the following interest: the Swiss Centre for Applied Human Toxicology is beneficiary of a grant from the Swiss Government in the context of the European Project Partnership for the Assessment of Risks from Chemicals (PARC). In accordance with EFSA's Policy on Independence<sup>1</sup> and the Decision of the Executive Director on Competing Interest Management<sup>2</sup>, and taking into account the specific matters discussed at the meeting in question, the interest was not deemed to represent a Conflict of Interest for the expert concerned. The expert Christopher Topping is the beneficiary of the Framework Partnership Agreement (FPA) –

<sup>1</sup> [http://www.efsa.europa.eu/sites/default/files/corporate\\_publications/files/policy\\_independence.pdf](http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/policy_independence.pdf)

<sup>2</sup> [http://www.efsa.europa.eu/sites/default/files/corporate\\_publications/files/competing\\_interest\\_management\\_17.pdf](http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/competing_interest_management_17.pdf)



GP/EFSA/SCER/2021/02: ApisRAM implementation for its use in the risk assessment of PPPs. The expert left the meeting when item 7 was discussed.

## **4. Scientific topic(s) for discussion**

### **4.1. Opinion on the use and reporting historical control data (HCD) for regulatory studies ([EFSA-Q-2021-00274](#))**

The Panel was updated on the status and planning of the activities. It was agreed that the development of a methodology on the use of HCD to inform the priors in the Benchmark Dose (BMD) analysis is considered out of the scope of the current mandate and that recommendations for future work will be provided by the Working Group (WG).

## **5. On-going activities of the Scientific Committee**

The Panel was informed on the on-going activities of the Scientific Committee (SC). The following activities were presented:

- Mandate on exposure and risk assessment of Bromide
- Biomarkers of effect
- CRA of pesticides and other chemicals
- Read across guidance

## **6. Opinion on toxicological properties and maximum residue levels of acetamiprid and its metabolites**

The Panel was informed on the EC mandate requesting EFSA's advice on whether the new scientific evidence that has become available since the renewal of acetamiprid in 2018, warrants a re-evaluation of the toxicological properties of acetamiprid and its metabolites. In addition, according to the mandate the residue definition in plants should be reconsidered based on monitoring studies.

## **7. Guidance on the use of the benchmark dose approach in risk assessment and related workshop**

The revised Guidance on the use of the benchmark dose approach in risk assessment was presented mainly focusing on the changes compared to the previous version.

## **8. Environmental scenarios for ApisRam version 3, a honeybee colony for pesticide risk assessment (MUST-b WG)**

The approach taken by the MUST-b WG for the definition of environmental scenarios to be implemented in ApisRAM was presented. The Panel was asked for feedback.



## **9. AOB**

The Panel was informed on the preliminary main outcomes of the Lot 1 of the project GP/EFSA/ENCO/2020/02 on microbiome for humans and animals which will be finalised in November 2023.

## **10. Next meeting**

The next meeting will be held on 28<sup>th</sup> September 2023, via web-conference.